Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study
MWN-AI** Summary
Sona Nanotech Inc. (CSE: SONA; OTCQB: SNANF) has announced an upcoming investor webinar scheduled for March 18, 2026, at 3:30 PM ET. The focus of this session will be to present follow-up data from the company's first-in-human study of its Targeted Hyperthermia Therapy (THT), which has shown promising preliminary results. The study involved ten late-stage melanoma patients who had not responded to standard immunotherapy. Notably, the treatment generated immune responses in 80% of the treated tumors, with a complete clinical response observed in 60% within just two weeks.
Participants will hear insights from Dr. Carlos Rojas, the study's principal investigator, along with Sona's CEO David Regan and CMO Dr. Carman Giacomantonio. The discussion will delve into patient follow-up results and highlight an abscopal effect experienced by one patient, where a treatment induced clinical responses in untreated tumors.
David Regan expressed excitement about sharing these findings, emphasizing the considerable response rates that THT demonstrated as a monotherapy and its potential to not only treat tumors but also enhance the effectiveness of subsequent therapies. The THT approach employs infrared light to activate gold nanorods that emit therapeutic heat to stimulate immune response, shrink tumors, and enhance drug delivery to tumor tissues.
The webinar will provide an opportunity for investors to engage directly with the research team. A recording will be made available afterward on the company's website's Investor Information section. As Sona moves forward, the company underscores that while the preliminary results are encouraging, future outcomes are uncertain and depend on various regulatory and clinical milestones.
MWN-AI** Analysis
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) is poised to grab investor attention as it prepares to host a webinar on March 18th, focusing on the promising results from its first-in-human clinical study of Targeted Hyperthermia Therapy (THT) for cancer treatment. The preliminary results, which indicate an 80% clinical response rate and a noteworthy abscopal effect in a small cohort of late-stage melanoma patients, suggest that THT could offer a novel approach in the oncological landscape.
As Sona gears up to share further data, including patient follow-up assessments, it is imperative for investors to analyze several aspects of this opportunity. The reported complete responses in 60% of the treated tumors, combined with the data on the abscopal effect—where untreated tumors also exhibited response—highlight the potential of THT to not only treat existing tumors effectively but possibly enhance the efficacy of other cancer therapies.
However, while the preliminary results are encouraging, investors must remain cautious. The success of experimental therapies often hinges on further clinical validation and regulatory approval. The environment for biotech firms can be volatile, especially when considering the lengthy and unpredictable nature of clinical trials and the associated capital requirements. Investors should monitor upcoming data, and regulatory milestones closely to assess the likelihood of Sona securing necessary approvals and funding for ongoing and future studies.
In summary, Sona Nanotech's developments present an intriguing investment opportunity, but a prudent approach involves a careful evaluation of associated risks and the broader competitive landscape. Attending the upcoming webinar could provide deeper insights into Sona’s prospects, critical for making informed investment decisions. Investors should consider a "hold" strategy until clearer signals about THT's feasibility emerge post-webinar and subsequent analyses.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
HALIFAX, NS , March 16, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), will host an investor webinar on Wednesday, March 18th at 3:30pm ET to discuss follow-up data from its first-in-human study of its Targeted Hyperthermia Therapy ("THT") (the "Study") that resulted the generation of immune responses in 8/10 treated and biopsied tumors, with complete responses seen in 6/10. Interested parties can register for this webinar via the following link: https://us06web.zoom.us/webinar/register/WN_D93hvFoCRO2589nPzO-JIQ
Joining on the webinar will be the study's principal investigator, Dr. Carlos Rojas, executive director of the Centro de Investigacion Clinica, Bradford Hill, along with Sona's CEO, David Regan, and CMO, Dr. Carman Giacomantonio. Data to be presented will include patient follow-up assessments, including evidence that THT treatments generated a clinical response in secondary, untreated tumors, known as an abscopal effect, in a Study patient. This study of ten, late-stage melanoma patients who had failed on standard-of-care immunotherapy protocols, was undertaken to assess the safety, tolerability and efficacy of THT in humans.
David Regan, Sona's CEO, commented, "We are excited to be able to share our perspectives on some follow-up data from our first-in-human study from the Principal Investigator. While the Study was intended to assess THT's safety, tolerability and ability to prime tumors for further treatment, THT given as a monotherapy treatment demonstrated in an astounding 80% clinical response rate ("CRR"), with 60% of treated, biopsied tumors cleared in only two weeks. In particular, evidence of an abscopal effect will be discussed with an opportunity for participants to question the study's Principal Investigator."
A recording of the webinar will be made available following the webinar in the Investor Information section of the Company's website.
About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.
Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy and its ability to become a viable treatment in humans cleared by regulators, and Sona's preclinical and clinical study plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to secure the remaining required regulatory approvals for the Pilot Study, enroll study participants in a timely manner, successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Sona Nanotech Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2026/16/c1979.html
FAQ**
What specific follow-up data from the first-in-human study of Sona Nanotech Inc. SNANF's Targeted Hyperthermia Therapy has shown clinical efficacy in secondary tumors, particularly regarding the observed abscopal effect?
Can you elaborate on the safety and tolerability profile of Sona Nanotech Inc. SNANF’s Targeted Hyperthermia Therapy as observed in the late-stage melanoma patient cohort?
How does Sona Nanotech Inc. SNANF plan to address the potential regulatory challenges mentioned in the forward-looking statements regarding the advancement of Targeted Hyperthermia Therapy?
What are the anticipated next steps for Sona Nanotech Inc. SNANF following the promising results from the first-in-human study, and how will these insights influence future clinical trials or developments?
**MWN-AI FAQ is based on asking OpenAI questions about Sona Nanotech Inc - Ordinary Shares (CNQC: SONA:CC).
NASDAQ: SONA:CC
SONA:CC Trading
-2.56% G/L:
$0.19 Last:
191,439 Volume:
$0.18 Open:
